In the third issue of our new special newsletter "SCHLAGLICHT – New Medications for Dementia," Dr. Nikolas Dietzel, a research associate at digiDEM Bayern, discusses the publication by scientists from Europe, the USA, and Australia, led by Professor Poul F. Høilund-Carlsen from Odense University Hospital in Denmark. In the article titled "Donanemab, another anti-Alzheimer’s…"
SPOTLIGHT – New Medications for Dementia – this is the name of our new series on new active ingredients for the treatment of Alzheimer's disease. We want to shed „spotlight“ on the multifaceted topic of „New Dementia Medications and Challenges for Everyday Care.“ These new medications are intended for people in the early stages of the disease or in the mild phase...
Many people worldwide hope to halt memory loss in dementia. Since June 2021, the drug Aducanumab has been approved in the USA for the treatment of Alzheimer's disease – but not in Europe. In our fact check, you can learn more about its effectiveness and why strict scientific criteria are important when evaluating a...
A new drug has been approved in the US, sparking a global controversy within Alzheimer's research. This is because 10 out of 11 reviewers rejected the drug for the treatment of Alzheimer's disease. The dementia group of the Cochrane Institute provides a brief overview of the evidence for Aducanumab. For a long time, there was...
